Expert Opinion on Drug Discovery,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 21
Published: April 29, 2025
Snakebite
envenoming
is
a
neglected
tropical
disease
that
affects
millions
globally
each
year.
In
recent
years,
research
into
the
potential
production
of
recombinant
antivenoms,
formulated
using
mixtures
highly
defined
anti-toxin
monoclonal
antibodies,
has
rapidly
moved
from
theoretical
concept
to
demonstrations
practical
feasibility.
This
article
examines
significant
advancements
in
transitioning
antivenoms
clinical
translation.
The
authors
have
based
their
review
on
literature
obtained
Google
Scholar
and
PubMed
between
September
November
2024.
Coverage
includes
development
validation
antivenom
antibody
discovery
strategies,
characterization
first
broadly
neutralizing
toxin
class
translational
proof-of-concept
experiments.
transition
'concept'
current
situation
where
high-throughput
anti-venom
mAb
becoming
routine,
accompanied
by
increasing
evidence
broad
capacity
vivo,
been
extraordinary.
It
now
important
build
this
momentum
expanding
mAbs
encompass
as
many
classes
possible.
anticipated
key
whether
can
match
or
surpass
existing
conventional
polyvalent
terms
scope
will
be
achieved
next
few
years.
Signal Transduction and Targeted Therapy,
Journal Year:
2025,
Volume and Issue:
10(1)
Published: March 5, 2025
The
successful
approval
of
peptide-based
drugs
can
be
attributed
to
a
collaborative
effort
across
multiple
disciplines.
integration
novel
drug
design
and
synthesis
techniques,
display
library
technology,
delivery
systems,
bioengineering
advancements,
artificial
intelligence
have
significantly
expedited
the
development
groundbreaking
drugs,
effectively
addressing
obstacles
associated
with
their
character,
such
as
rapid
clearance
degradation,
necessitating
subcutaneous
injection
leading
increasing
patient
discomfort,
ultimately
advancing
translational
research
efforts.
Peptides
are
presently
employed
in
management
diagnosis
diverse
array
medical
conditions,
diabetes
mellitus,
weight
loss,
oncology,
rare
diseases,
additionally
garnering
interest
facilitating
targeted
platforms
advancement
vaccines.
This
paper
provides
an
overview
present
market
clinical
trial
progress
therapeutics,
platforms,
It
examines
key
areas
through
literature
analysis
emphasizes
structural
modification
principles
well
recent
advancements
screening,
design,
technologies.
accelerated
including
peptide-drug
complexes,
new
vaccines,
innovative
diagnostic
reagents,
has
potential
promote
era
precise
customization
disease
therapeutic
schedule.
Journal of Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Feb. 6, 2025
Nanobodies
(Nbs),
miniature
antibodies
consisting
solely
of
the
variable
region
heavy
chains,
exhibit
unique
properties
such
as
small
size,
high
stability,
and
strong
specificity,
making
them
highly
promising
for
disease
diagnosis
treatment.
The
engineering
production
Nbs
has
evolved
into
a
mature
process,
involving
library
construction,
screening,
expression
purification.
Different
types,
including
immune,
naïve,
synthetic/semi-synthetic
libraries,
offer
diverse
options
various
applications,
while
display
platforms
like
phage
display,
cell
surface
non-surface
provide
efficient
screening
target
Nbs.
Recent
advancements
in
artificial
intelligence
(AI)
have
opened
new
avenues
Nb
engineering.
AI's
exceptional
performance
protein
structure
prediction
molecular
interaction
simulation
introduced
novel
perspectives
tools
design
optimization.
Integrating
AI
with
traditional
experimental
methods
is
anticipated
to
enhance
efficiency
precision
development,
expediting
transition
from
basic
research
clinical
applications.
This
review
comprehensively
examines
latest
progress
engineering,
emphasizing
construction
strategies,
platform
technologies,
It
evaluates
strengths
weaknesses
libraries
explores
potential
challenges
predicting
structure,
antigen-antibody
interactions,
optimizing
physicochemical
properties.
Biomaterials Advances,
Journal Year:
2023,
Volume and Issue:
151, P. 213428 - 213428
Published: April 24, 2023
More
than
fifty
years
after
the
3Rs
definition
and
despite
continuous
implementation
of
regulatory
measures,
animals
continue
to
be
widely
used
in
basic
research.
Their
use
comprises
not
only
vivo
experiments
with
animal
models,
but
also
production
a
variety
supplements
products
origin
for
cell
tissue
culture,
cell-based
assays,
therapeutics.
The
animal-derived
most
research
are
fetal
bovine
serum
(FBS),
extracellular
matrix
proteins
such
as
Matrigel™,
antibodies.
However,
their
raises
several
ethical
issues
regarding
welfare.
Additionally,
biological
is
associated
high
risk
contamination,
resulting,
frequently,
poor
scientific
data
clinical
translation.
These
support
search
new
animal-free
able
replace
FBS,
antibodies
In
addition,
silico
methodologies
play
an
important
role
reduction
by
refining
previously
vitro
experiments.
this
review,
we
depicted
current
available
alternatives
ImmunoHorizons,
Journal Year:
2023,
Volume and Issue:
7(12), P. 886 - 897
Published: Dec. 1, 2023
Abstract
mAbs
are
highly
indispensable
tools
for
diagnostic,
prophylactic,
and
therapeutic
applications.
The
first
technique,
hybridoma
technology,
was
based
on
fusion
of
B
lymphocytes
with
myeloma
cells,
which
resulted
in
generation
single
against
a
specific
Ag.
Along
several
novel
alternative
methods
have
been
developed
to
improve
mAb
generation,
ranging
from
electrofusion
the
discovery
completely
technologies
such
as
cell
immortalization;
phage,
yeast,
bacterial,
ribosome,
mammalian
display
systems;
DNA/RNA
encoded
Abs;
technology;
transgenic
animals;
artificial
intelligence/machine
learning.
This
commentary
outlines
evolution,
methodology,
advantages,
limitations
various
production
techniques.
Furthermore,
advent
next-generation
Ab
single-chain
variable
fragments,
nanobodies,
bispecific
Abs,
Fc-engineered
biosimilars,
mimetics,
Ab-drug
conjugates,
healthcare
pharmaceutical
sectors
become
resourceful
develop
treatments
diseases
cancer
autoimmune
infectious
diseases.
Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
14(8), P. 3362 - 3384
Published: April 10, 2024
Drug
discovery
is
a
sophisticated
process
that
incorporates
scientific
innovations
and
cutting-edge
technologies.
Compared
to
traditional
bioactivity-based
screening
methods,
encoding
display
technologies
for
combinatorial
libraries
have
recently
advanced
from
proof-of-principle
experiments
promising
tools
pharmaceutical
hit
due
their
high
efficiency,
throughput,
resource
minimization.
This
review
systematically
summarizes
the
development
history,
typology,
prospective
applications
of
displayed
technologies,
including
phage
display,
ribosomal
mRNA
yeast
cell
one-bead
one-compound,
DNA-encoded,
peptide
nucleic
acid-encoded,
new
peptide-encoded
examples
preclinical
clinical
translation.
We
discuss
progress
novel
targeted
therapeutic
agents,
covering
spectrum
small-molecule
inhibitors
nonpeptidic
macrocycles
linear,
monocyclic,
bicyclic
peptides,
in
addition
antibodies.
also
address
pending
challenges
future
prospects
drug
discovery,
size
libraries,
advantages
disadvantages
technology,
translational
potential,
market
space.
intended
establish
comprehensive
high-throughput
strategy
researchers
developers.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: April 30, 2024
Over
160
therapeutic
and
in
vivo
diagnostic
monoclonal
antibodies
have
been
approved
by
the
US
FDA
since
first
antibody,
muromonab,
was
1986.
Approximately
42%
of
these
approvals
were
for
treatment
or
diagnosis
oncology
indications,
although
some
products
are
no
longer
marketed.
This
review
will
look
at
history
antibody
development
approvals,
discuss
current
antibody-based
modalities,
regulatory
considerations
engineering
approaches,
critical
quality
attributes
different
immunogenicity
mAbs
across
products,
future
directions
products.
